Presentation is loading. Please wait.

Presentation is loading. Please wait.

Poliomyelitis. Instructional Objectives: At the end of the lecture the student would be able to: 1-Demonstrate the main clinical characteristics of poliomyelitis.

Similar presentations


Presentation on theme: "Poliomyelitis. Instructional Objectives: At the end of the lecture the student would be able to: 1-Demonstrate the main clinical characteristics of poliomyelitis."— Presentation transcript:

1 Poliomyelitis

2 Instructional Objectives: At the end of the lecture the student would be able to: 1-Demonstrate the main clinical characteristics of poliomyelitis. 2-Point out the occurrence of the disease. 3-List the causative agent, mode of transmission, incubation period, and period of communicability of poliomyelitis. 4-List the main preventive measures of poliomyelitis. 5-Describe the control measures of poliomyelitis. 6-Define the WHO strategies of polio eradication.

3 Polio virus infection occur in GI tract with spread to regional LN and in minority of cases to CNS

4 Flaccid paralysis occurs in <1 % of polio virus infection >90% of infections are either in apparent or non specific fever Aseptic meningitis occurs in about 1% of infections Clinical responses are extremely varied

5  In apparent: Paralytic polio=200:1  Minor illness: Manifested as low grade fever, malaise, headache, nausea & vomiting (10%)

6 major illness: Manifested as Sever muscle spasm, followed by Neck & back stiffness, it ends with flaccid paralysis:  Asymmetrical  Maximized within 3-4 days  Site is depend on the location of nerve cell destruction in the spinal cord or brain stem  Legs are affected more than arms  Proximal parts more often than distal parts

7  Affected muscles are floppy, reflexes are diminished,sense of pain & touch remain normal  Residual paralysis is usually present after 60 days  Severe cases : quadriplegia, abdomen & thoracic muscles, bulbar polio

8 Differential diagnosis of Acute flaccid paralysis (AFP):  Paralytic polio  Guillian Barre syndrome  Transverse myelititis  Traumatic neuritis  Acute motor axonal neuropathy  Encephalitis  Meningitis  Tumors

9 Distinguishing characteristics:  Asymmetrical flaccid paralysis  Fever at onset  Rapid progression of paralysis  Residual paralysis after 60 days  Preservation of sensory nerve function

10 Causative agent : Entero virus : Type 1 2 & 3  Paralytogenic less commonly  Most frequent frequent cause  Cause of outbreak of vaccine associated.

11 Occurrence : Prior to immunization it had a world wide distribution. It is eradicated from the western Hemispheres & industrialized countries If cases appeared in industrialized countries they are either imported or vaccine associated

12 Age of distribution: Remains primarily a disease of infants & young children,in many polio endemic regions 70-80% of cases are <3 years of age & 80-90% are <5 years of age

13 Reservoir : Human most frequently persons with in apparent infections. Long term carriers have not been found.

14 Mode of transmission:  Direct person to person principally through fecal –oral transmission - bad standard of sanitation - young children  Pharyngeal droplets - good sanitation - older age groups  Food, milk, & other materials contaminated with feces rare  Insects no reliable evidence exists  Water,sewage, rarely implicated.

15 Incubation period:  7- 14 days for paralytic cases  Reported range of 3-35 days Period of communicability:  Not precisely defined  Transmission is possible as long as the virus is excreted  Virus appeared in throat secretion as early as 36 hrs & in feces 72 hrs after exposure to infection  Virus persists in the throat for (1) week &in the feces for 3-6 weeks

16 Prevention: Education of public on the advantages of immunization in early childhood Vaccination trivalent (OPV) inactivated (IPV)

17 OPV: Advantages: Recommended by WHO for polio eradication &EPI 3 doses will protect at least 80-85 % of immunized children Induces both circulating antibody &intestinal resistance. Immunize some susceptible contacts through secondary spread Low cost, (however)

18 OPV: Disadvantages: Low rates of seroconversion in developing countries It is contra indicated in all immune deficient persons Vaccine associated paralysis (VAPP) 1:2.5,000,000 doses (1:800000 in 1 st dose) Lower level of serum antibodies (break down in the cold chain, acute diarrhea, or local intestinal immunity)

19

20 Reading the vaccine vial monitor ((VVM))

21 IPV:  Prevents paralytic polio by producing sufficient Antibodies In the serum  It has no risk of vaccine associated paralysis  Lower level of intestinal immunity  More expensive.

22 The recommended schedule of immunization in Iraq rootvaccinesage ID+ORAL+IMB.C.G+POLIO(0)+HB11 week IM+ORAL+IMD.P.T(1)+POLIO(1)+HB22 Months IM+ORALD.P.T(2)+POLIO(2)4 Months IM+ORAL+IMD.P.T(3)+POLIO(3)+HB36 Months SC+ORALMEASLES+VIT A9 Months SCM.M.R15Months ORAL+IMFIRST.B00STER POLIO+D.P.T 18-24 Months ORAL+IM2 nd..B00STER POLIO+D.P.T 4-6 Years

23 Control: Reporting is obligatory any case of AFP under 15 y should be fully investigated (clinical, epidemiological, and stool culture) Isolation Concurrent disinfection Protection of contacts Inv of source No Sp Rx

24 Polio Eradication : Polio is one of only a limited number of diseases they can be eradicated  Polio only affects human  An effective vaccine is available  Immunity is life long  No long term carriers  No animal or insect reservoir  Virus can only survive for a very short period in the environment

25 Strategy of Eradication:  High routine immunization coverage with OPV i.e giving the 4 basic doses during the 1 st year of life  Supplementary immunization in the form of mass campaigns or NIDs  Effective surveillance.  Final stage when Very few or no cases are occurring,door-to-door immunization campaigns (mopping up) in areas where the virus persists.


Download ppt "Poliomyelitis. Instructional Objectives: At the end of the lecture the student would be able to: 1-Demonstrate the main clinical characteristics of poliomyelitis."

Similar presentations


Ads by Google